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General information
The project “The role of microparticles in pathomecha-
nisms of diabetic retinopathy – analysis of intercellu-
lar communication mechanisms in endothelial aging” 
was awarded by the Polish National Science Center 
(NCN) in the 7th edition of OPUS competition under 
grant number 2012/07/B/NZ5/02510. The contract 
between NCN and Jagiellonian University Medical Col-
lege (JUMC) was signed on 26th of June 2013 and the 
duration of the project is planned for 36 month, until 
25th of June 2016.
The clinical part of the projects is a prospective 
case-control study in a group of diabetic patients with 
a high risk of retinopathy. The project is interdisciplin-
ary in nature and requires a close co-operation of spe-
cialists in clinical and laboratory medicine and basic 
science.
This project aims to combine recent progress in 
molecular and cell biology with the new approach for 
understanding the sequence of events on molecular 
and cellular levels leading to diabetic retinopathy (DR). 
The project adds a new piece of puzzle to understand-
ABSTRACT
The project is proposed to explain the role of specifi c circulating microparticles (MPs) as conveyors in traffi cking 
bio-active molecules in type 1 (T1DM) and type 2 (T2DM) diabetic patients with risk of diabetic retinopathy (DR) 
and in patients with metabolic syndrome (MS). The possible role of miRNAs as modulators of these processes (in 
switching on/off mechanism on the molecular level) is proposed. An increased number of MPs with respect to 
glucose concentrations and levels of proangiogenic factors in vivo (patients’ plasma) is expected. The relationship 
between age of patents and MP content (cell membrane glycoproteins, phosphatidylserine or miRNA profi le) 
is possible. MPs will be obtained from T1DM (n = 30) T2DM (n = 30), MS (n = 30) and controls (n = 30). 
Retinopathy in diabetic patients will be assessed by imaging method. Biological profi le of MPs will be assessed in 
vitro by means of fl ow cytometry, molecular biology methods and cell proliferation assays.
Keywords: microparticles, endothelium, diabetic retinopathy, miRNA, vascular ageing.
T HE  R AT I O N A L E  A ND  DE S I G N  A ND  M E T H O DS  O F  NE W  S T U DIE S
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ing how hyperglycemic conditions affect retina, vascu-
lar (endothelial) and beta-cells to secretion of micropar-
ticles (MPs). It is assumed to characterize MPs released 
in this way (miRNA content), and compare this charac-
teristic with in vivo conditions, with MPs obtained from 
metabolic syndrome, T1DM and T2DM patients.
Management
The Principal Investigator of this project is Associate 
Professor Ewa Stępień (PhD), a specialist in laboratory 
medicine (genetics) from Department of Medical Phys-
ics Jagiellonian University and Department of Clinical 
Biochemistry JUMC.
Co-investigators are: Professor Maciej Małecki (MD, 
PhD) from Department of Metabolic Disease JUMC, 
Iwona Szuścik (MD, PhD) from Private Ophthalmology 
Practice OKO-LASER Outpatient Clinic in Kraków, Asso-
ciate Professor Bogdan Solnica (MD, PhD) and Aleksan-
dra Tokarz (MSc) from Department of Clinical Biochem-
istry JUMC and Aleksander Żurakowski from Depart-
ment of Interventional Cardiology, American Heart of 
Poland SA, Chrzanów. 
The International Partner is Assistant Professor 
Francisco J. Enguita (BPharm, PhD) from Instituto de 
Medicina Molecular, Faculdade de Medicina, Universi-
dade de Lisboa, Portugal.
Ethics
Bioethical Committee at JUMC accepted all proj-
ect’s protocols and forms, including information for 
patients form and consent form for participation in the 
research study on 24th October 2013. The permission 
No. KBET/206/B/2013 is valid until 31st of December 
2016.
Finance 
The project is mainly fi nanced by a grant from NCN 
Life Science Panel in the 7th OPUS call dedicated to 
“Human and animal noninfectious diseases mecha-
nisms, diagnosis and treatment of diseases, poison-
ings and injuries”. The total amount of grant funding is 
697,100 PLN (about 169,000 Euro). Grant funds were 
earmarked to purchase reagents for molecular biology, 
biochemistry and fl ow cytometry methods, disposable 
laboratory equipment, laboratory instrumentation for 
the conducting of proposed research and data analysis. 
In addition, grant funds were designed to cover person-
nel costs of project participants and costs associated 
with the dissemination of research results, i.e., through 
publications in peer reviewed journals and presenta-
tions at professional scientifi c conferences.
Research basic concept
Microparticles (MP) are small extracellular vesicles 
between 100 and 500 nm, released by the cells in a 
strictly regulated, cytoskeleton dependent process. In 
contrast, exosomes are smaller in diameter (between 
40 and 100 nm) and they are released during consti-
tutive or facultative exocytosis [1]. MPs are produced 
during shedding process in response to some stressing 
factors like: hypoxia and injury or due to infl ammation 
[2]. A number of cell types associated with the vascular 
system have been shown to release MPs: platelets, lym-
phocytes, macrophages, vascular endothelial cells and 
others (smooth muscle, retina, progenitor and cancer 
cells) [3, 4]. MPs have been suggested to mediate local 
infl ammation, thus they play a pivotal role in vascular 
diseases, such as atherosclerosis or DR [5, 6].
Endothelial dysfunction occurs when perturbed 
homeostatic endothelium disrupts vascular compe-
tence. These disruptions result in reduced vasodilata-
tion, increased proinfl ammatory and prothrombotic 
property of the vascular network [7]. New insight in 
endothelial dysfunction, including the process of angio-
genesis alteration is emerging from studies on vascular 
microvesicles such as endothelial MPs. It was previously 
documented that MPs derived from activated or apop-
totic endothelial cells induce apoptosis in circulating 
angiogenic cells, and impair the atheroprotective and 
angiogenic function of the endothelium [8]. Impaired 
endothelial function is thought to be a denomina-
tor of pathogenesis of microvascular complications in 
T1DM and T2DM. It was documented that DR is associ-
ated with increased intima-media thickness (IMT) and 
endothelial dysfunction measured as concentrations 
of von Willebrand factor (vWF) and s-ICAM-1 [10] and 
elevated circulating ADMA [9].
MPs of endothelial, platelet, photoreceptor, and 
microglial origin were identifi ed in vitreous samples 
and increased MPs of different origin in patients with 
DR may contribute to disease progression. The pro-
infl ammatory and pro-coagulation effects of MPs are 
mediated by specifi c lipid composition and/or by the 
transfer of pro-infl ammatory factors from the cells 
of origin [11]. Moreover, endothelial microparticles 
(EMPs), released from apoptotic endothelial cells (ECs), 
infl uence cell repair of glucose damaged ECs by trans-
ferring microRNA [13].
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Research objectives
The study primary objective is to characterize the pro-
fi le of circulating MPs containing cell derived microR-
NA. This should allow to explain the mechanisms trig-
gering undesirable events: thrombosis, apoptosis and 
degenerative vasculogenesis, which lead to DR.
One of the proposed mechanisms of DR is increased 
MP release from platelets and endothelial cells trig-
gering TF in patients with complicated diabetes [14]. 
Apart from up-regulating effect on the expression of 
growth factors and chemokines, TF may directly pro-
mote ocular angiogenesis by the activation of MAPK- 
and protein kinase C-dependent signalling (non-canon-
ical pathways). Another mechanism proposes the trans-
fer of secondary messenger molecules (receptors, lip-
ids) mainly from immune cells (lymphocytes T), which 
regulates vascular function [15, 16]. It was proposed, 
that failed angiogenesis in metabolic diseases is regu-
lated by down-expression of vascular growth factors, 
via miRNA [17].
The secondary objective is the confi rmation wheth-
er the exposure of endothelial cells to MPs generated 
in hyperglycemic conditions can induce calcium infl ux, 
cytoskeleton reorganization, VE-cadherin expression 
and catenin-beta translocation. It is important to dis-
tinguish the specifi c elements in this process, especially 
MPs content (miRNA) and their phenotype (origin) in 
the regulation of this machinery. This part of a study 
will be performed in vitro, in a cell culture model.
Research plan
The proposed project will be composed of two stag-
es: Clinical stage – selection of individuals to 4 study 
groups T1DM (n = 30) T2DM (n = 30), MS (n = 30) 
and controls (n = 30) and analysis of classical risk 
factors and biomarkers; Basic stage – quantifi cation 
Figure 1. Work plan of the study “The role of microparticles in pathomechanisms of diabetic retinopathy - analysis of intercellular com-
munication mechanisms in endothelial aging. Case control study in patients with metabolic syndrome, diabetes type 1 and type 2"
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of MPs, miRNA profi ling, in vitro investigation. Time 
course of particular tasks is presented on Figure 1.
Research methodology
Study population
Up to 90 patients and 30 control subjects in age 
between 25–65 years will be enrolled into this study. 
All participants will be classifi ed into 4 groups match-
ing the inclusion criteria (Table 1). MS was will be 
defi ned according to the revised ATPIII criteria that 
require at least three of the following components: (1) 
abdominal obesity (waist circumference ≥ 102 cm for 
men or ≥ 88 cm for women), (2) triglycerides ≥ 150 
mg/dL, (3) HDL cholesterol ≤ 40 mg/dL for men or 50 
mg/dL for women or lipids lowering therapy, (4) systol-
ic/diastolic blood pressure ≥ 130/85 mmHg or receiv-
ing drug treatment, and (5) fasting plasma glucose ≥ 
100 mg/dL [18].
Assessment of clinical outcomes
Length of time from entry to the study to when the 
clinical event will occur is planned no less than 2 years. 
Clinical outcomes will be assessed in primary and sec-
ondary end-points (Table 2).
Sample collection
All blood samples will be drawn at the same time of the 
day (between 08:00 and 10:00 am) with venipuncture 
with > 21-gauge needle in the antecubital vein follow-
ing the application of a tourniquet. The fi rst 2–3 ml of 
blood will not be included for MP analysis (used for 
additional analysis). Citrate (for MPs and miRNAs) or 
EDTA (hematology, HbA1C, biomarkers) anticoagula-
tion will be used. For biochemistry, serum samples will 
be collected. The blood samples will be separated to 
obtain Platelet Poor Plasma (PPP) or serum and frozen 
at -80°C until analysis for miRNAs and selected bio-
markers. Additionally, urine samples will be collected.
Table 2. Clinical outcomes of the project
Primary end-points
An anatomic feature that is measured at the end of a study to assess the progression of DR: measure the area of choroidal 
neovascularization, submacular leakage and hemorrhage
Secondary end-points Statistically and clinically relevant differences in visual function at more than one time point
Table 1. Eligibility and inclusion criteria for patients enrolled to the project “The role of microparticles in pathomechanisms of diabetic retinopathy – 
analysis of intercellular communication mechanisms in endothelial aging. Case control study in patients with metabolic syndrome, diabetes type 1 and 
type 2”
Type 1 Diabetes Mellitus (T1DM)
n = 30







Male and female subjects in age between 25–65 years
Subjects who will give their informed consent to participate in the study, both in the enrolment and later follow-up.
Diabetes type 1 Diabetes type 2
Metabolic syndrome according to 
revised ATPIII criteria [18]
apparently healthy
BMI from 18.5 to 24.9/m2
BMI from 25.0 to 40.0/m2
BMI from 18.5 to 24.9/m2
BMI from 25.0 to 40.0/m2
BMI from 30 to 40.0 kg/m2 BMI from 18.5 to 24.9 kg/m2
Diabetic Retinopathy (DR) assessed 
by the colorful photographic 
documentation of two 
45° retinal fi elds
Diabetic Retinopathy (DR) assessed 
by the colorful photographic 
documentation of two 
45° retinal fi elds
– –
Insulin resistance is not an 
exclusion criterion




Acute Coronary Syndrome (ACS), acute Ischemic Stroke (IS) or critical limb ischemia will be excluded from this study. 
A previous cardiovascular event (MI or IS) has to be at least 6 months prior to the study enrollment.
History of cancer, renal and liver failure, and past or present systemic infl ammation (hs-CRP > 10 mg/l), 
such as active chronic arthritis or phospholipid syndrome.
Known or suspected bacterial or viral infection
Treatments with steroidal and non-steroidal anti-infl ammatory drugs, bariatric surgery
Pregnancy or Hormone Replacement Therapy (HRT)
Morbid obesity > 40.0 0 kg/m2 Morbid obesity > 40.0 0 kg/m2 Morbid obesity > 40.0 0 kg/m2 –
– – – Statin treatment
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Laboratory analysis
Standard blood tests including biochemistry (glucose, 
lipids, creatinine) will be performed. For biomarkers, 
ELISA and molecular biology methods are planned. MP 
enumeration and phenotype analysis will be performed 
by fl ow cytometry. Genetic analysis of miRNA profi le 
and gene expression will be done by means of quantita-
tive PCR methods or next generation (NG) sequencing. 
Cell culture methods will be used for assessment of MP 
induced endothelial proliferation and angiogenesis.
Statistical analysis and methodology
The hazard ratio for data summary and the risk assess-
ment will be performed. The linear regression models 
will be used for the continuous variable analysis, like 
biomarkers and MPs enumeration. MicroRNA will be 
correlated with biomarkers levels and the MPs num-
ber using multiple regression models. The Cox pro-
portional hazard regression model will be used for DR 
parameters with respect to MPs and miRNA covariates. 
Additionally data mining analysis will be performed to 
reveal any data relationships.
Expected results
The clinical part of this study will be directed to devel-
op new methods and systems for diagnostics and treat-
ment of endothelial dysfunction related to pathologi-
cal endothelial proliferation/neovascularization, senes-
cence and other hyperglycemia related defects that 
cause defi ciencies of ocular system:
development and application of universal diagnos- –
tics protocols,
discovery of new biomarkers, –
manufacturing of new diagnostic tests, –
targeting of the disease (DR). –
The further basic research phase of this study may 
have an important role in the promoting the new 
experiments on circulating MPs and miRNAs and may 
have a high impact on the future technologies which 
apply new biomarkers in prophylaxis, treatment and 
prognosis of DR. In this stage we expect:
to verify the hypothesis about the mechanisms  –
involved in the processes related to DR on the cel-
lular level: cell-to-cell communication via MPs as 
transferring vesicles of regulatory molecules includ-
ing miRNAs and proangiogenic proteins,
to bring a new insight into the relation between  –
MP exposure, endothelial cell cytoskeleton reorga-
nization and activation of cell signaling,
to explain the role of MPs in neovascularization on  –
the molecular level.
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